Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone212-220-9226
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable
Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions
What is Applied Therapeutics' stock symbol?
Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."
How were Applied Therapeutics' earnings last quarter?
Applied Therapeutics (NASDAQ:APLT) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.14. View Applied Therapeutics' Earnings History.
When is Applied Therapeutics' next earnings date?
What price target have analysts set for APLT?
4 analysts have issued 12-month price objectives for Applied Therapeutics' stock. Their forecasts range from $43.00 to $65.00. On average, they anticipate Applied Therapeutics' stock price to reach $50.67 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price. View Analyst Price Targets for Applied Therapeutics.
What is the consensus analysts' recommendation for Applied Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Therapeutics.
Has Applied Therapeutics been receiving favorable news coverage?
News stories about APLT stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Applied Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Applied Therapeutics.
Are investors shorting Applied Therapeutics?
Applied Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 305,600 shares, an increase of 16.8% from the January 15th total of 261,600 shares. Based on an average trading volume of 172,400 shares, the days-to-cover ratio is currently 1.8 days. Approximately 3.7% of the company's stock are short sold. View Applied Therapeutics' Current Options Chain.
Who are some of Applied Therapeutics' key competitors?
Some companies that are related to Applied Therapeutics include GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), Emergent Biosolutions (EBS), Myokardia (MYOK), Axsome Therapeutics (AXSM), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Genmab A/S (GMAB) and Allakos (ALLK).
What other stocks do shareholders of Applied Therapeutics own?
Who are Applied Therapeutics' key executives?
Applied Therapeutics' management team includes the folowing people:
- Dr. Shoshana Shendelman Ph.D., Chairman, Founder, Pres, CEO & Sec. (Age 40)
- Dr. Mark Joseph Vignola, Chief Financial Officer (Age 42)
- Dr. Riccardo Perfetti, Chief Medical Officer (Age 59)
When did Applied Therapeutics IPO?
(APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.
Who are Applied Therapeutics' major shareholders?
Applied Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Emerald Mutual Fund Advisers Trust (3.41%), FMR LLC (1.30%), Artisan Partners Limited Partnership (0.85%), Sofinnova Investments Inc. (0.62%), Oppenheimer & Co. Inc. (0.43%) and State Street Corp (0.39%). Company insiders that own Applied Therapeutics stock include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman and Stacy J Kanter. View Institutional Ownership Trends for Applied Therapeutics.
Which major investors are selling Applied Therapeutics stock?
Which major investors are buying Applied Therapeutics stock?
APLT stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Emerald Mutual Fund Advisers Trust, Oppenheimer & Co. Inc., State Street Corp, Driehaus Capital Management LLC, Geode Capital Management LLC, Barclays PLC and Emerald Advisers LLC. Company insiders that have bought Applied Therapeutics stock in the last two years include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman and Stacy J Kanter. View Insider Buying and Selling for Applied Therapeutics.
How do I buy shares of Applied Therapeutics?
Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Applied Therapeutics' stock price today?
One share of APLT stock can currently be purchased for approximately $43.19.
How big of a company is Applied Therapeutics?
What is Applied Therapeutics' official website?
How can I contact Applied Therapeutics?
Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]
MarketBeat Community Rating for Applied Therapeutics (NASDAQ APLT)
MarketBeat's community ratings are surveys of what our community members think about Applied Therapeutics and other stocks. Vote "Outperform" if you believe APLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
